TxCell

TxCell develops cellular immunotherapy platforms based on antigen-specific regulatory T cells for the treatment of severe autoimmune and inflammatory diseases as well as transplantation-related inflammatory disorders.

Revenue(FY, 2016)

€2.9 M

Market capitalization(2017-10-31)

€31.3 M

Type

Public

Valbonne, FR

Founded

2001

Size (employees)

57 (est)+10%

Website

txcell.com

TxCell was founded in 2001 and is headquartered in Valbonne, FR

Report incorrect company information

Key People/Management at TxCell

Stéphane Boissel

CEO

Raphaël Flipo

SVP & CFO

Francois Meyer

Chairman of the Board and Head of Research

Report incorrect company information

TxCell Office Locations

TxCell has an office in Valbonne

Valbonne, FR (HQ)

Allée de la Nertière

Show all (1)

Report incorrect company information

TxCell Financials and Metrics

TxCell Financials

TxCell's revenue was reported to be €2.95 m in FY, 2016 which is a 36.4% decrease from the previous period.

Summary

EUR
Revenue (FY, 2016)	2.9 m
Revenue growth (FY, 2015 - FY, 2016), %	(36.4%)
Net income (FY, 2016)	(13.6 m)
EBIT (FY, 2016)	(12.8 m)
Market capitalization (31-Oct-2017)	31.3 m
Closing share price (31-Oct-2017)	1.6
Cash (31-Dec-2016)	3.5 m
EV	33 m

TxCell's current market capitalization is €31.3 m.

Income Statement

EUR	FY, 2014	FY, 2015	FY, 2016
Revenue	3.4 m	4.6 m	2.9 m
Revenue growth, %		36%	(36%)
General and administrative expense	2.2 m	3.5 m	4.5 m
R&D expense	7.8 m	10.8 m	10.5 m

show all

Balance Sheet

EUR	FY, 2014	FY, 2015	FY, 2016
Cash	13.9 m	9.2 m	3.5 m
Accounts Receivable	1 m	4 k	4 k
Current Assets	18.5 m	13.8 m	5.8 m
PP&E	1.4 m	876 k	736 k

show all

Cash Flow

EUR	FY, 2014	FY, 2015	FY, 2016
Net Income	(8.3 m)	(11.3 m)	(13.6 m)
Depreciation and Amortization	460 k	1.1 m	(326 k)
Accounts Payable	5.8 m	213 k	(714 k)
Cash From Operating Activities	(6.9 m)	(10.1 m)	(10.4 m)